Skip to main content

Report: New Cholesterol Drugs Too Costly

Newly approved drugs to lower cholesterol are priced much too high, according to the Institute for Clinical and Economic Review.

Lead image for this article

Newly approved drugs to lower cholesterol are priced much too high, according to the Institute for Clinical and Economic Review, an outside nonprofit which monitors cost and care issues. The companies that make the new drugs question the nonprofit’s methodology and some pharmacies have been pressing for significant discounts. (Wall Street Journal)

The Texas Tribune Member Drive Fall 2021 banner

Support public-service journalism that’s always free to read.

Yes, I'll donate today